1-3 of 3
Mark Boldrin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

Julio Rosenstock, MD, Bogdan Balas, MD, Bernard Charbonnel, MD, Geremia B. Bolli, MD, Mark Boldrin, MS, Robert Ratner, MD, Raffaella Balena, MD, for the T-emerge 2 Study Group
Journal: Diabetes Care
Diabetes Care 2013;36(3):498–504
https://doi.org/10.2337/dc12-0709
Published: 13 February 2013
View article titled, The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: <subtitle>The T-emerge 2 trial</subtitle>
Open the PDF for The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: <subtitle>The T-emerge 2 trial</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)

Itamar Raz, MD, Vivian Fonseca, MD, Mark Kipnes, MD, Laurence Durrwell, PHD, John Hoekstra, MD, Mark Boldrin, MS, Raffaella Balena, MD
Journal: Diabetes Care
Diabetes Care 2012;35(3):485–487
https://doi.org/10.2337/dc11-1942
Published: 10 February 2012
View article titled, Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: <subtitle>Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)</subtitle>
Open the PDF for Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: <subtitle>Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

Michael A. Nauck, MD, Robert E. Ratner, MD, Christoph Kapitza, MD, Rachele Berria, MD, Mark Boldrin, Raffaella Balena, MD, PHD
Journal: Diabetes Care
Diabetes Care 2009;32(7):1237–1243
https://doi.org/10.2337/dc08-1961
Published: 14 April 2009
View article titled, Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: <subtitle>A double-blind placebo-controlled study</subtitle>
Open the PDF for Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: <subtitle>A double-blind placebo-controlled study</subtitle> in another window
Includes: Supplementary data